Read More

Zealand Pharma Announced Global License and Development Agreement with Novo Nordisk for ZEGALOGUE; Zealand to Receive Upfront Payment of DKK 25M Plus Up to DKK 45M in Milestones

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® (dasiglucagon) for injection.